IRIS
ETTARI, Roberta
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.777
EU - Europa 2.995
AS - Asia 2.507
SA - Sud America 1.045
AF - Africa 81
Continente sconosciuto - Info sul continente non disponibili 4
OC - Oceania 2
AN - Antartide 1
Totale 10.412
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.686
SG - Singapore 1.108
BR - Brasile 925
IE - Irlanda 804
SE - Svezia 597
CN - Cina 596
IT - Italia 594
HK - Hong Kong 362
VN - Vietnam 184
DE - Germania 172
PL - Polonia 118
RU - Federazione Russa 118
GB - Regno Unito 112
UA - Ucraina 104
FI - Finlandia 103
FR - Francia 92
AT - Austria 75
IN - India 72
AR - Argentina 39
CA - Canada 39
MX - Messico 35
BD - Bangladesh 30
BE - Belgio 27
TR - Turchia 23
ZA - Sudafrica 23
MA - Marocco 22
EC - Ecuador 20
IQ - Iraq 20
ID - Indonesia 19
NL - Olanda 19
UZ - Uzbekistan 16
CO - Colombia 14
JP - Giappone 14
UY - Uruguay 12
ES - Italia 11
CZ - Repubblica Ceca 10
VE - Venezuela 10
PY - Paraguay 9
TN - Tunisia 9
AE - Emirati Arabi Uniti 7
CL - Cile 7
DZ - Algeria 7
PE - Perù 6
AZ - Azerbaigian 5
CI - Costa d'Avorio 5
GE - Georgia 5
KZ - Kazakistan 5
LT - Lituania 5
CH - Svizzera 4
DO - Repubblica Dominicana 4
EG - Egitto 4
IL - Israele 4
JM - Giamaica 4
LV - Lettonia 4
PK - Pakistan 4
SA - Arabia Saudita 4
SC - Seychelles 4
AL - Albania 3
BG - Bulgaria 3
BO - Bolivia 3
EU - Europa 3
GR - Grecia 3
JO - Giordania 3
KG - Kirghizistan 3
KR - Corea 3
LB - Libano 3
NI - Nicaragua 3
NP - Nepal 3
AM - Armenia 2
BA - Bosnia-Erzegovina 2
BY - Bielorussia 2
HN - Honduras 2
KE - Kenya 2
KW - Kuwait 2
MD - Moldavia 2
MU - Mauritius 2
MY - Malesia 2
RO - Romania 2
RS - Serbia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AD - Andorra 1
AO - Angola 1
AQ - Antartide 1
AU - Australia 1
BH - Bahrain 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
EE - Estonia 1
GA - Gabon 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LU - Lussemburgo 1
MK - Macedonia 1
MN - Mongolia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PH - Filippine 1
PR - Porto Rico 1
SI - Slovenia 1
Totale 10.407
Salva come PNG Salva come JPEG
Città #
Dublin 804
Chandler 547
Singapore 487
Ashburn 481
Nyköping 433
Hong Kong 362
Dallas 350
Beijing 316
Messina 247
Jacksonville 228
Princeton 127
Warsaw 116
Medford 114
Los Angeles 94
Dearborn 90
Des Moines 90
Cambridge 81
Ann Arbor 71
São Paulo 69
Vienna 69
Ho Chi Minh City 62
The Dalles 59
Buffalo 58
Redondo Beach 51
New York 44
Boardman 39
Hanoi 37
Lancaster 33
Munich 31
Rio de Janeiro 31
Jinan 30
San Mateo 30
Tianjin 26
Moscow 24
Brussels 23
Belo Horizonte 22
Hyderabad 22
Frankfurt am Main 21
Montreal 21
Rome 21
Aversa 20
Santa Clara 20
Curitiba 19
Wilmington 18
Brasília 17
Stockholm 17
Brooklyn 16
Campinas 15
Chicago 15
Pune 15
Tashkent 15
Houston 14
San Francisco 14
Shenyang 14
Lauterbourg 13
Porto Alegre 13
Seattle 13
Woodbridge 13
Düsseldorf 12
Johannesburg 12
Montpellier 12
Tokyo 12
Atlanta 11
Boston 11
Denver 11
London 11
Mexico City 11
Taizhou 11
Augusta 10
Dong Ket 10
Guarulhos 10
Haikou 10
Helsinki 10
Montevideo 10
Nanjing 10
Palermo 10
Zhengzhou 10
Amsterdam 9
Baghdad 9
Bari 9
Biên Hòa 9
Hebei 9
Manaus 9
Phoenix 9
Poplar 9
Uberlândia 9
Catania 8
Chennai 8
Da Nang 8
Haiphong 8
Milan 8
Mumbai 8
Salvador 8
Turku 8
Ankara 7
Bexley 7
Brno 7
Francofonte 7
Siderno 7
São José dos Campos 7
Totale 6.533
Salva come PNG Salva come JPEG
Nome #
BAY 11-7082 inhibits the NF-κB and NLRP3 inflammasome pathways and protects against IMQ-induced psoriasis 177
Exploiting Curcumin Synergy With Natural Products Using Quantitative Analysis of Dose–Effect Relationships in an Experimental In Vitro Model of Osteoarthritis 146
Design, synthesis and biological evaluation of novel rhodesain inhibitors for the treatment of Human African Trypanosomiasis 131
Identification of 2-thioxoimidazolidin-4-one derivatives as novel noncovalent proteasome and immunoproteasome inhibitors 129
Non-covalent immunoproteasome inhibitors induce cell cycle arrest in multiple myeloma cells 126
Synthesis and biological evaluation of novel peptidomimetics as rhodesain inhibitors 122
Constrained peptidomimetics as antiplasmodial falcipain-2 inhibitors 119
Cross-Metathesis Reactions in the Synthesis of Constrained Dipeptide Mimics as Potent Falcipain-2 Inhibitors. 118
Design, synthesis and molecular modeling studies on peptidomimetic vinyl esters as falcipan-2 inhibitors 116
Design, synthesis and biological evaluation of novel dipeptide-like rhodesain inhibitors containing a conformationally constrained 3-bromoisoxazoline warhead 115
DEVELOPMENT OF NOVEL PEPTIDOMIMETIC ANALOGUES OF A HIGHLY POTENT AND SELECTIVE FALCIPAIN-2 INHIBITOR CONTANING A VINYL ESTER MOIETY 114
Identification of noncovalent proteasome inhibitors with high selectivity for chymotrypsin-like activity by a multistep structure-based virtual screening 113
G-Protein-Coupled Receptor Kinase 2 (GRK2) Inhibitors: Current Trends and Future Perspectives 111
Cross-Metathesis Reactions in the Synthesis of Constrained Dipeptide Mimics as Potent Falcipain-2 Inhibitors 109
Role of the microbiota in hematologic malignancies. 109
Design and synthesis of novel isoxazole-based HDAC inhibitors 108
Development of novel 1,4-benzodiazepine-based Michael acceptors as antitrypanosomal agents 106
Immunoproteasome-selective and non-selective inhibitors: A promising approach for the treatment of multiple myeloma. 106
Design and NMR conformational analysis in solution of β5i-selective inhibitors of immunoproteasome 105
Development of novel irreversible rhodesain inhibitors as antitrypanosomal agents. 105
Development of Urea-Bond-Containing Michael Acceptors as Antitrypanosomal Agents Targeting Rhodesain 103
A novel benzodiazepine derivative that suppresses microtubule dynamics and impairs mitotic progression 103
Peptidomimetics containing a vinyl ketone warhead as falcipain-2 inhibitors 102
Evaluation of curcumin irreversibility 102
Chloro-substituted Hoveyda-Grubbs ruthenium carbene: investigation of electronic effects 101
Immunoproteasome-selective inhibitors: a promising strategy to treat hematologic malignancies, autoimmune and inflammatory diseases 101
Novel peptidomimetics containing different α,β-unsaturated electrophilic functions, as falcipain-2 inhibitors 100
A novel 2,3-benzodiazepine-4-one derivative AMPA antagonist inhibits G2/M transition and induces apoptosis in human leukemia Jurkat T cell line 99
Development of Novel Peptidomimetics Containing a VinylSulfone Moiety as Proteasome Inhibitors 99
Development of Novel Peptide-based Michael Acceptors Targeting Rhodesain and Falcipain-2 for the Treatment of Neglected Tropical Diseases (NTDs) 98
Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei rhodesiense 98
Discovery of novel peptidomimetics containing a benzodiazepine scaffold as inhibitors of rhodesain of Trypanosoma brucei rhodesiense 97
Development of novel benzodiazepine-based peptidomimetics as inhibitors of rhodesain of Trypanosoma brucei rhodesiense 97
Falcipain-2 inhibitors 95
Drug combination studies of curcumin and genistein against rhodesain of Trypanosoma brucei rhodesiense 95
Design, synthesis and biological evaluation of peptidomimetics boronic acids targeting 20S proteasome 91
Development of novel amides as non covalent inhibitors of immunoproteasome 91
Development of novel dipeptide-like rhodesain inhibitors containing the 3-bromoisoxazoline warhead in a constrained conformation 91
The Inhibition of Cysteine Proteases Rhodesain and TbCatB: A Valuable Approach to Treat Human African Trypanosomiasis 90
Formation of 3-Aminofuran-2-(5H)-ones and 3-Amino-1H-pyrrole-2,5-diones by Rearrangement of Isoxazolidines 89
Identification of novel 5 arylidene-3-phenyl-2 thioxoimidazolidin-4-ones as inhibitors of the chymotrypsin-like activities of the constitutive and immuno-proteasomes 89
Development of pyridin-2-one derivatives as non-covalent inhibitors of immunoproteasome 89
Reazioni di cross metathesis: applicazione alla sintesi di peptidomimetici potenziali inibitori di falcipaina-2 88
Chloro-substituted Hoveyda-Grubbs ruthenium carbene: Investigation of electronic effects 88
Development of novel N-3-bromoisoxazolin-5-yl substituted 2,3-benzodiazepines as noncompetitive AMPAR antagonists 88
Development of novel peptide-based Michael acceptors targeting rhodesain and falcipain-2 for the treatment of neglected tropical diseases (NTDs) 88
Mechanism of Inhibition of the GluA2 AMPA Receptor Channel Opening: The Role of 4-Methyl versus 4-Carbonyl Group on the Diazepine Ring of 2,3-Benzodiazepine Derivatives 86
Development of peptidomimetic boronates as proteasome inhibitors 86
Development of novel 1,4-benzodiazepines as antitrypanosomal agents 86
Composti antitumorali 86
Development of novel dipeptide nitriles as inhibitors of rhodesain of Trypanosoma brucei hodesiense 85
DEVELOPMENT OF NOVEL PEPTIDOMIMETICS CONTAINIG A VINYL SULFONE MOIETY AS PROTEASOME INHIBITORS 84
DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF PEPTIDOMIMETIC FALCIPAIN-2 INHIBITORS AS ANTIMALARIAL AGENTS 84
Development of novel peptide-based Michael acceptors as antitrypanosomal agents 84
Synthesis of novel peptidomimetics as inhibitors of protozoan cysteine proteases falcipain-2 and rhodesain 82
Synthesis and biological evaluation of new 2-amino-6-(trifluoromethoxy)benzoxazole derivatives, analogues of riluzole. 81
Optimization Strategy of Novel Peptide-Based Michael Acceptors for the Treatment of Human African Trypanosomiasis 81
Glutamate Binding-Site Ligands of NMDA Receptors 80
Development of peptidomimetic boronates as proteasome inhibitors 80
Development of peptidyl Michael acceptors for S3 pocket investigation of rhodesain, cysteine protease of Trypanosoma brucei rhodesiense 80
Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors 79
Drug repositioning for the treatment of hematologic disease: limits, challenges and future perspectives 79
Alarmins and MicroRNAs, a New Axis in the Genesis of Respiratory Diseases: Possible Therapeutic Implications 78
Development of Novel Selective Peptidomimetics Containing a Boronic Acid Moiety, Targeting the 20S Proteasome as Anticancer Agents 78
Development of isoquinolinone derivatives as immunoproteasome inhibitors. 78
Development of Peptidomimetics with a Vinyl Sulfone Warhead as Irreversible Falcipain-2 Inhibitors 77
Synthesis and Molecular Modeling Studies of Derivatives of a Highly Potent Peptidomimetic Vinyl Ester as Falcipain-2 Inhibitors 77
Novel peptidomimetic cysteine protease inhibitors as potential antimalarial agents 76
Novel peptidomimetics containing a β-turn mimetic 1,4-Benzodiazepine scaffold as falcipain-2 inhibitors 76
Development of nonpeptidic vinyl and allyl phosphonates as active-site-directed inhibitors of falcipain-2 76
Novel 2H-isoquinolin-3-ones as antiplasmodial falcipain-2 inhibitors 76
Development of novel peptidyl nitriles targeting rhodesain and falcipain-2 for the treatment of sleeping sickness and malaria 75
Nonpeptidic Vinyl and Allyl Phosphonates as Falcipain-2 Inhibitors 75
Novel peptidomimetics as antiplasmodial falcipain-2 inhibitors 75
Drug combination studies of isoquinolinone AM12 with curcumin or quercetin: a new combination strategy to synergistically inhibit 20S proteasome 74
Synthesis of constrained dipeptide mimics containing the benzodiazepine scaffold 74
Synthesis and anti-HIV activity evaluation of new phenyl ethyl thiourea (PET) derivatives 74
Novel peptidomimetic cysteine protease inhibitors as antimalarial agents 73
Optimization of peptidomimetic boronates bearing a P3 bicyclic scaffold as proteasome inhibitors 73
Synthesis of Peptidomimetics with the Benzodiazepine Nucleus as beta-turn mimic 73
Cross-metathesis reactions applications to the synthesis of peptidomimetics as potent falcipain-2 inhibitors 73
Recent Advances in Nanotherapeutics for Multiple Myeloma 73
Development of novel Michael acceptors targeting rhodesain as antitrypanosomal agents 72
Effect of mammalian SERCA inhibitors on Plasmodium falciparum growth in vitro 71
Mechanism and Site of Inhibition of AMPA Receptors: Substitution of One and Two Methyl groups at the 4-Aminophenyl Ring of 2,3-Benzodiazepine and Implications in the “E” Site 71
Formaldehyde exposure and acute myeloid leukemia: A review of the literature 70
Discovery of novel antitrypanosomal agents: design, synthesis of novel benzodiazepine-based peptidomimetics targeting rhodesain, the main cysteine protease of Trypanosoma brucei rhodesiense 70
Blunting Neuroinflammation by Targeting the Immunoproteasome with Novel Amide Derivatives 68
Identification of a new series of non-covalent proteasome inhibitors with selectivity for β5-subunits 68
Lead discovery of SARS-CoV-2 main protease inhibitors through covalent docking-based virtual screening 68
NMR conformational analysis in solution of a potent class of cysteine proteases inhibitors 67
Novel Peptidomimetics Containing a Vinyl Ester Moiety as Highly Potent and Selective Falcipain-2 Inhibitors 66
Synthesis and pharmacological evaluation of α4β2 nicotinic ligands with a 3-fluoropyrrolidine nucleus 65
A proteomic platform unveils the brain glycogen phosphorylase as a potential metabolic target for glioblastoma multiforme 65
Novel 2H-Isoquinolin-3-ones Falcipain-2 Inhibitors as Antimalarial Agents 64
Development of novel peptide-based Michael acceptors targeting rhodesain for the treatment of human african trypanosomiasis 64
Development of reduced peptide bond pseudopeptide Michael acceptors for the treatment of Human African Trypanosomiasis 63
Structure-based lead optimization of peptide-based vinyl methyl ketones as SARS-CoV-2 main protease inhibitors 62
Progettazione e sintesi di nuovi inibitori del proteasoma quali potenti agenti antitumorali 61
Development of Rhodesain Inhibitors with a 3-Bromoisoxazoline Warhead 61
Totale 8.880
Salva come PNG Salva come JPEG
Categoria #
all - tutte 42.778
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.778
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021414 0 0 0 0 0 85 23 55 81 107 29 34
2021/2022771 11 104 6 48 14 6 65 25 7 53 133 299
2022/20232.281 182 201 103 179 141 229 36 148 959 4 76 23
2023/2024589 69 72 41 143 55 48 6 8 3 62 33 49
2024/20252.463 41 21 44 157 92 56 75 460 676 175 236 430
2025/20262.768 306 531 538 656 689 48 0 0 0 0 0 0
Totale 10.962